Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.96 NOK | -2.30% | -5.40% | -22.60% |
Apr. 03 | ContextVision Announces New Image Quality Advancements in X-Ray | CI |
Feb. 16 | Transcript : ContextVision AB, Q4 2023 Earnings Call, Feb 16, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- This company will be of major interest to investors in search of a high dividend stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.60% | 41.75M | C- | ||
+4.36% | 32.47B | C | ||
+14.14% | 7.45B | C- | ||
+22.93% | 3.89B | B- | ||
-16.29% | 3.15B | C- | ||
-25.96% | 1.28B | B | ||
-36.14% | 1.09B | - | ||
-35.42% | 902M | - | ||
-0.13% | 893M | C | ||
-24.12% | 857M | - | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CONTX Stock
- Ratings ContextVision AB